Delving into the Latest Updates on Bambuterol Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate), Bambuterol, Bambuterol Hydrochloride Capules

+ [11]

Target

β2-adrenergic receptor

Action

agonists

Mechanism

β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Immune System DiseasesRespiratory DiseasesDigestive System Disorders

Active Indication

AsthmaPulmonary Disease, Chronic ObstructiveInflammatory Bowel Diseases

Inactive Indication-

Originator Organization

AstraZeneca UK Ltd.

Active Organization

Hainan Zhongyu Medicine Co. Ltd.

AstraZeneca Pharmaceuticals Co. Ltd.

Suzhou Kaifa Biotechnology Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1999),

AsthmaPulmonary Disease, Chronic Obstructive

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H29N3O5

InChIKeyANZXOIAKUNOVQU-UHFFFAOYSA-N

CAS Registry81732-65-2

View All Structures (2)

To study the pharmacokinetics of the test preparation bambuterol hydrochloride tablets and the reference preparation bambuterol hydrochloride tablets (Bangbei®) in healthy adult subjects after a single oral dose in the fasting/postprandial state, and to evaluate the bioequivalence and safety of the two preparations when taken orally in the fasting/postprandial state.

Start Date11 Apr 2023

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

CTR20222261

/ CompletedNot Applicable

评估受试制剂盐酸班布特罗片与参比制剂盐酸班布特罗片（帮备®）在健康成年受试者中的单中心、开放、随机、单剂量、双交叉空腹/餐后生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, double-crossover fasting/fed bioequivalence study to evaluate the test formulation of bambuterol hydrochloride tablets and the reference formulation of bambuterol hydrochloride tablets (Bangbei®) in healthy adult subjects

研究空腹/餐后状态下单次口服受试制剂盐酸班布特罗片与参比制剂盐酸班布特罗片（帮备®）在健康成年受试者体内的药代动力学，评价空腹/餐后状态下口服两种制剂的生物等效性和安全性。

[Translation]

To study the pharmacokinetics of the test preparation bambuterol hydrochloride tablets and the reference preparation bambuterol hydrochloride tablets (Bangbei®) in healthy adult subjects after a single oral dose in the fasting/postprandial state, and to evaluate the bioequivalence and safety of the two preparations in the fasting/postprandial state.

Start Date09 Oct 2022

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

NCT01796730

/ CompletedPhase 4IIT

A 12-week, Double-blind, Multicenter, 3-crossover, Placebo Controlled and Randomized Trial to Investigate the Efficacy and Safety of 10mg and 5mg Bambuterol Tablets Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This is a randomized, double-blind, 3-crossover trial with a 7-days washout baseline period followed by three treatment periods of 21-days each performed in patients with COPD. Patients will be randomized to receive three treatments (bambuterol 10mg, bambuterol 5 mg and placebo).

Start Date01 Feb 2013

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

[+2]

100 Clinical Results associated with Bambuterol Hydrochloride

Login to view more data

100 Translational Medicine associated with Bambuterol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Bambuterol Hydrochloride

Login to view more data

559

Literatures (Medical) associated with Bambuterol Hydrochloride

01 Feb 2025·Analytical and Bioanalytical Chemistry

LC-HRMS screening procedure for the detection of 11 different classes of prohibited substances in dried urine spots for doping control purposes

Article

Author: Tsivou, Maria ; Pizzolato, Francesca ; Honesová, Lenka ; Gmeiner, Günter ; Mazzarino, Monica ; Van Eenoo, Peter

Dried urine spots have recently been proposed as an alternative matrix in the anti-doping field. Drying urine may open the opportunity to limit microbial and thermal degradation of the prohibited substances during transportation to the anti-doping laboratories without the need for refrigeration or freezing. In this study, a multi-targeted initial testing procedure was developed for the determination of 237 prohibited drugs/metabolites from 11 different classes in dried urine spots. The comparability between two different microsampling techniques (i.e., Whatman^® FTA DMPK-C cards and Mitra^® tips) was evaluated. The developed method was then used to evaluate the stability of the target compounds in urine for 7 days under different environmental conditions to simulate the transportation of the urine samples from the collection sites to anti-doping laboratories. Sample preparation consists of (i) extraction of the analytes from the collection device using a mixture of acetonitrile/methanol (1/1) for 30 min at 40 °C, (ii) enzymatic hydrolysis, and (iii) sample concentration by solid-phase extraction. Analysis was performed using liquid chromatography coupled to high-resolution mass spectrometry. The entire workflow was validated in terms of specificity (analytes were distinguishable from the matrix interferences), sensitivity (only with the Mitra^® tips the limits of detection comply with the World Anti-Doping Agency's requirements for the majority of the target compounds), carry-over (no signals in the negative urine injected after the positive urine), matrix effect (16-28% for Mitra^® tips and 22-35% for DMPK-C cards), and extraction yield (Mitra^® tips: 51-88%; DMPK-C cards: 40-76%). As proof of concept, authentic urine samples were analyzed: results obtained in dried urine were compared with those of fluid urine, providing good agreement. Stability studies showed that the target compounds were stable for the whole duration of the study (7 days) at -20 and 4 °C in both fluid and dried urine. At 50 °C or at 20-25 °C, several thiazide-based compounds were completely degraded to their degradation product in the first 24 h or after 3-4 days in fluid urine, whereas in dried urine the compounds were detectable for the entire duration of the study.

01 Nov 2024·Journal of Chromatography A

Clindamycin phosphate-based deep eutectic solvent as a chiral selector for enantioseparation of amino alcohol drugs in nonaqueous capillary electrophoresis

Article

Author: Ma, Xiaofei ; Zhang, Chengchen

Clindamycin phosphate (CP) exhibits good enantioselectivity for many basic drugs, but its separation effect for most amino alcohol drugs is not satisfactory. In this work, a deep eutectic solvent (DES) chiral selector based on CP was prepared for the first time and utilized as a single chiral selector in nonaqueous capillary electrophoresis (NACE) to separate twelve amino alcohol drugs. Compared with unmodified CP, the separations of model drugs in the DES chiral selector system were significantly improved. Most amino alcohol drugs could be completely separated, and the peak shapes were good. In addition, we used infrared spectroscopy and nuclear magnetic resonance method to study the specific separation mechanism and explored the reasons why DES chiral selector has better enantioselectivity. This work is the first to directly modify antibiotic chiral selector into DES, indicating a direction for us to develop novel chiral recognition materials.

01 Nov 2024·Chemical Engineering Journal

A target-triggered domino platform for multimode-guided lateral flow immunoassay of multiple β-agonists

Author: Qiu, Yulou ; Zhang, Biao ; Yu, Xiaoping ; Zhang, Chenxu ; Zhang, Xuecheng ; Lin, Xiaodong ; Sun, Kai ; Lang, Yihan ; Shentu, Xuping

Beta-agonists are seriously threatening the human health because of their illegal used in foods.In this work, a lateral flow immunoassays (LFIA) were developed for multimode determination of residues of ten β-agonists in real samples.Here, the developed platform used Ms-Pd/Pt-pAbNPs nanoprobes, fabricated by decorating the surface of Mulberry-shaped Palladium/Platinum nanoparticels (Ms-Pd/PtNPs) with self-prepared broad-spectrum polyclonal antibody (pAb).Through a competitive strategy, salbutamol as the analyte, a visual sensing mode was realized by the Ms-Pd/Pt-pAbNPs being trapped on the surface of test line (T line), offering a limit of detection (LOD) of 1.0 ng/mL with naked eye.Subsequently, Ms-Pd/Pt-pAbNPs with oxidase-like performance catalyzes the TMB into oxTMB with blue color, achieving a detection range from 0.01 to 100 ng/mL based on the colorimetric sensing LFIA, with an LOD as low as 0.01 ng/mL and 75-fold lower than that of traditional immunoassay (ELISA).Then, the oxTMB converts near-IR (NIR) laser into energy, causing a photothermal-based LFIA for detection of salbutamol range from 0.01 to 100 ng/mL with an LOD as low as 0.01 ng/mL as well as 75-fold lower than of ELISA.The target triggered reactions like "a domino platform" was constructed for detection of a series of targets in multimodal-based LFIA, contributing to the as-prepared pAb with broad comibation capability.Meanwhile, the developed multimodal LFIA enabled to detect salbutamol in pork, beef, and animal feed samples with satisfactory recovery.Consequently, the integrated output signals in this multimodal LFIA enhanced the assays flexibility, utility, and accuracy, performing well as a point-of-care testing platform for various application scenarios.

100 Deals associated with Bambuterol Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07489	Bambuterol Hydrochloride	R03CC12	DB01408

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Asthma	China	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1999
Pulmonary Disease, Chronic Obstructive	China	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammatory Bowel Diseases	IND Approval	China	Hainan Zhongyu Medicine Co. Ltd.	28 Jun 2022
Inflammatory Bowel Diseases	IND Approval	China	Suzhou Kaifa Biotechnology Co. Ltd.	28 Jun 2022